Date: 2015-04-29
Type of information: Grant
Company: Epigenomics (Germany - USA)
Investors: European Commission’s Horizon 2020 programme
Amount: € 2.77 million
Funding type: grant
Planned used: The grant will fund the clinical research to validate Epigenomics’ proprietary lung cancer biomarkers with the goal to develop a CE-marked product for the detection of lung cancer in blood plasma under the new in-vitro diagnostic directive.
Others: * On April 29, 2015, Epigenomics announced that the Company will receive an EU grant under the industrial leadership Horizon 2020 research and innovation program for SME (Small and Medium-Sized Enterprises). The grant duration is expected to be 24 months with a total fund volume of up to € 2.77 million.
Therapeutic area: Cancer - Oncology - Diagnostic
